Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections
By Mauro Orru
Roche Holding AG said Monday that a Phase 3 trial involving
casirivimab and imdevimab to cut risk of symptomatic Covid-19
infections yielded positive results, meeting primary and key
The Swiss pharmaceutical major said the trial showed the
subcutaneous administration of casirivimab and imdevimab lowered
risk of symptomatic Covid-19 infections by 81%.
Casirivimab and imdevimab also cut the overall risk of
progressing to symptomatic Covid-19 by 31% in recently-infected
"Although vaccinations are increasing globally, there remains a
critical unmet need world-wide to prevent infections and provide
immediate protection from Covid-19 between close contacts. This is
why we are excited to bring this data to health authorities with
the goal of making the combination available to more people as soon
as possible," Roche's chief medical officer and head of global
product development Levi Garraway said.
Roche said Regeneron Pharmaceuticals Inc. would share new data
with the Food and Drug Administration in the U.S., with the two
companies agreeing to cooperate with the European Medicines Agency
and other health authorities.
Write to Mauro Orru at firstname.lastname@example.org; @MauroOrru94
(END) Dow Jones Newswires
April 12, 2021 01:37 ET (05:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.